GoAI
Get started
Check-Cap Ltd. Ordinary Share logo

Check-Cap Ltd. Ordinary Share

MBAI

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$8.04

+$0.02 · +0.25%

Aug 21, 4:00 PM ET

MBAI company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

91

Deep Value

Momentum

18

Strong Down

Sentiment

52

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
IL
CEO
David Lontini
Listed since
Mar 4, 2015
Employees
85

Market position

Day range

Current $8.04

52-week range

Current $8.04

Open
$8.0321
Previous close
$8.02
Volume
4.4K
0.04× average
Average volume
107.52K
Average daily volume
Market cap
8.06M USD
Beta
0.82
Market reference 1
50-day average
$8.3604
-3.83% below average
200-day average
$10.9227
-26.39% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.11M USD
P/E (TTM)
1.74×
P/B (TTM)
2.08×
P/S (TTM)
0×
EV / EBITDA
2.32×
Earnings yield
41.01%
Free cash flow yield
-0.46%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
120.45%
Return on assets
55.30%
Return on invested capital
-68.72%

Financial health

Debt / equity
0×
Current ratio
0.05×

Financial statements

Income trends

Operating income

−2.37M USD+90.86%

Net income

4.14M USD+29.29M USD
Income trends across reported periods7.15M USD−4.89M USD−16.92M USD−28.96M USDOperating income, FY2021: −17.32M USDOperating income, FY2022: −20.03M USDOperating income, FY2023: −19.29M USDOperating income, FY2024: −25.95M USDOperating income, FY2025: −2.37M USDNet income, FY2021: −17.2M USDNet income, FY2022: −19.11M USDNet income, FY2023: −17.57M USDNet income, FY2024: −25.15M USDNet income, FY2025: 4.14M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −17.32M USD. Operating income FY2022 −20.03M USD. Operating income FY2023 −19.29M USD. Operating income FY2024 −25.95M USD. Operating income FY2025 −2.37M USD. Net income FY2021 −17.2M USD. Net income FY2022 −19.11M USD. Net income FY2023 −17.57M USD. Net income FY2024 −25.15M USD. Net income FY2025 4.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development——8.31M USD14.27M USD12.35M USD
Selling, general, and administrative2.34M USD9.3M USD9.46M USD5.65M USD4.94M USD
Operating expenses2.37M USD25.95M USD19.29M USD20.03M USD17.32M USD
Interest income172K USD809K USD1.77M USD1.05M USD101K USD
Interest expense185K USD9K USD13K USD12K USD13K USD
Depreciation and amortization34K USD161K USD212K USD404K USD205K USD
Operating income−2.37M USD−25.95M USD−19.29M USD−20.03M USD−17.32M USD
Net income4.14M USD−25.15M USD−17.57M USD−19.11M USD−17.2M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
4.62
FY2025
Latest fiscal-year revenue
0 USD
FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend8.09-5.8-19.68-33.57FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend0.10.03-0.03-0.1FY21FY22FY23FY24FY25

MBAI news

globenewswire.com

Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective

Check-Cap Ltd. (NASDAQ: MBAI) advanced its proposed merger with physical AI company, MBody AI Corp., completing a planned 1-for-7 reverse share split Check-Cap Ltd. (NASDAQ: MBAI) advanced its proposed merger with…

Read source
globenewswire.com

Check-Cap Advances MBody AI Merger; Reverse Share Split

ISFIYA, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: MBAI) today announced that the Company will implement a 1-for-7 reverse share split (the “Reverse Share Split”) of…

Read source
globenewswire.com

Check-Cap Announces Reverse Share Split

ISFIYA, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: MBAI) today announced a 1-for-7 reverse share split (the “Reverse Share Split”) of the Company's ordinary shares.

Read source
globenewswire.com

Check-Cap: MBody AI Takes Autonomous Services Outdoors, Expanding Addressable Market

Nasdaq-listed Check-Cap (NASDAQ: MBAI): MBody AI secures exclusive U.S. rights to outdoor cleaning robots in gaming and hospitality across six states. Nasdaq-listed Check-Cap (NASDAQ: MBAI): MBody AI secures exclusive…

Read source
globenewswire.com

Check-Cap (MBAI) Sets Eight-Week Target for MBody AI Merger

Check-Cap Ltd. (NASDAQ: MBAI) has publicly filed its Form F-1 and now expects its merger with MBody AI Corp. to close within the next eight weeks Check-Cap Ltd. (NASDAQ: MBAI) has publicly filed its Form F-1 and now…

Read source
globenewswire.com

Check-Cap: MBody AI Advances Its Robot Fleet Operating System with Multi-Robot Control

ISFIYA, Israel and LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: MBAI) today announced that its merger partner, MBody AI Corp. (“MBody AI”), has added multi-robot…

Read source

MBAI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research MBAI

research.disclaimer